T
Tioma Therapeutics
Venture-stage biopharmaceutical company
About Tioma Therapeutics
Tioma Therapeutics, Inc., operating as a venture-stage biopharmaceutical company, focuses on the immuno-oncology sector. The company directs its efforts towards developing and discovering anti-CD47 antibodies for treating both solid and hematologic cancers. Founded in 2006 as Vasculox, Inc., the firm underwent a rebranding to Tioma Therapeutics in 2016, and later became known as Arch Oncology. The company was established by scientific founder William A. Frazier, a professor at Washington University School of Medicine who was pivotal in discovering that CD47 is a receptor for thrombospondin-1. This foundational research underpins the company's entire therapeutic platform.
The company’s core business revolves around developing a portfolio of therapeutic antibodies that target CD47 signaling pathways. The primary product candidates are immune checkpoint inhibitors designed to block the CD47 protein, which cancer cells use to send a "don't eat me" signal to the immune system. By inhibiting this signal, Tioma's antibodies enable the innate and adaptive immune systems to recognize and attack tumor cells. This approach is being evaluated for various applications, including the treatment of cancer, pulmonary hypertension, and preventing complications from solid organ transplants. The business model is centered on advancing its antibody portfolio through clinical trials to establish proof-of-concept, with the ultimate goal of commercialization or strategic partnerships within the pharmaceutical industry.
A significant milestone in the company's history was securing an $86 million Series A financing in August 2016. This round was co-led by prominent venture capital firms, including RiverVest Venture Partners, Novo Ventures, Roche Venture Fund, and S.R. One, the corporate venture arm of GlaxoSmithKline. The funding was allocated to advance the lead drug candidate through human clinical trials and further develop the antibody portfolio. Operationally, the company maintains its research laboratories in St. Louis, Missouri, while its corporate headquarters are located in the San Francisco Bay Area.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 24.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Immune System, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Apr 2021 | $105M | $420M | Adage Capital · Broadfin · RiverVest Venture Partners · Point72 | ↗ |
| SERIES BOther financing | Mar 2019 | $50M | $200M | Cultivation Capital · RiverVest Venture Partners · Roche Venture Fund | ↗ |
Growth signals
Latest recorded traffic for Tioma Therapeutics is 110 monthly website visits. Tioma Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Tioma Therapeutics in the St. Louis ecosystem
The Tioma Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Cultivation Capital
Series A4 investors entered at this stage
SR One
RiverVest Venture Partners
Roche Venture Fund
Novo Ventures
Series B and later3 investors entered at this stage
Adage Capital- BRBroadfin
Point72
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tioma Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tioma Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










